US2006240063A9PendingUtilityA9
Medical implants and fibrosis-inducing agents
Est. expiryNov 10, 2023(expired)· nominal 20-yr term from priority
A61P 9/00A61P 43/00A61K 38/39A61L 2300/412A61B 17/11A61B 17/68A61B 17/12022A61P 19/00A61K 38/363A61L 2430/38A61K 45/06A61P 1/00A61B 17/12168A61B 17/1214A61B 17/12099A61L 2300/00A61B 17/1219A61K 38/4833A61L 31/16A61B 17/12109A61L 27/54A61K 38/38A61B 17/12186A61F 2250/0067
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
Claims
exact text as granted — not AI-modified1 - 493 . (canceled)
494 . A method comprising introducing into a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at a specific site within the patient, thereby providing the patient with hernia repair.
495 . (canceled)
496 . The method of claim 494 wherein the agent promotes angiogenesis.
497 . The method of claim 494 wherein the agent promotes fibroblast migration.
498 . The method of claim 494 wherein the agent promotes fibroblast proliferation.
499 . The method of claim 494 wherein the agent promotes deposition of extracellular matrix (ECM).
500 . The method of claim 494 wherein the agent promotes tissue remodeling.
501 . The method of claim 494 wherein the agent is an arterial vessel wall irritant.
502 . The method of claim 494 wherein the fibrosing agent is or comprises silk.
503 . (canceled)
504 . (canceled)
505 . The method of claim 494 wherein the fibrosing agent is or comprises chitosan.
506 . The method of claim 494 wherein the fibrosing agent is or comprises polylysine.
507 . The method of claim 494 wherein the fibrosing agent is or comprises fibronectin.
508 . The method of claim 494 wherein the fibrosing agent is or comprises bleomycin.
509 . The method of claim 494 wherein the fibrosing agent is or comprises CTGF.
510 .- 531 . (canceled)
532 . The method of claim 494 , wherein the composition further comprises a second pharmaceutically active agent.
533 . (canceled)
534 . The method of claim 494 , wherein the composition further comprises an agent that inhibits infection.
535 .- 6769 . (canceled)
6770 . A medical device comprising a hernia mesh implant and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
6771 . (canceled)
6772 . The device of claim 6770 wherein the fibrosing agent promotes angiogenesis.
6773 . The device of claim 6770 wherein the fibrosing agent promotes fibroblast migration.
6774 . The device of claim 6770 wherein the fibrosing agent promotes fibroblast proliferation.
6775 . The device of claim 6770 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
6776 . The device of claim 6770 wherein the fibrosing agent promotes tissue remodeling.
6777 . The device of claim 6770 wherein the fibrosing agent is an arterial vessel wall irritant.
6778 . (canceled)
6779 . (canceled)
6780 . The device of claim 6770 wherein the fibrosing agent is or comprises silk.
6781 . (canceled)
6782 . The device of claim 6770 wherein the fibrosing agent is or comprises chitosan.
6783 . The device of claim 6770 wherein the fibrosing agent is or comprises polylysine.
6784 . The device of claim 6770 wherein the fibrosing agent is or comprises fibronectin.
6785 . The device of claim 6770 wherein the fibrosing agent is or comprises bleomycin.
6786 . The device of claim 6770 wherein the fibrosing agent is or comprises CTGF.
6787 .- 6841 . (canceled)
6842 . The device of claim 6770 , further comprising a second pharmaceutically active agent.
6843 . (canceled)
6844 . The device of claim 6770 , further comprising an agent that inhibits infection.
6845 .- 9611 . (canceled)
9612 . A method of making a medical device comprising combining i) a hernia mesh implant, with ii) a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.
9613 . (canceled)
9614 . The method of claim 9612 wherein the fibrosing agent promotes angiogenesis.
9615 . The method of claim 9612 wherein the fibrosing agent promotes fibroblast migration.
9616 . The method of claim 9612 wherein the fibrosing agent promotes fibroblast proliferation.
9617 . The method of claim 9612 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
9618 . The method of claim 9612 wherein the fibrosing agent promotes tissue remodeling.
9619 . The method of claim 9612 wherein the fibrosing agent is an arterial vessel wall irritant.
9620 . (canceled)
9621 . (canceled)
9622 . The method of claim 9612 wherein the fibrosing agent is or comprises silk.
9623 . (canceled)
9624 . The method of claim 9612 wherein the fibrosing agent is or comprises chitosan.
9625 . The method of claim 9612 wherein the fibrosing agent is or comprises polylysine.
9626 . The method of claim 9612 wherein the fibrosing agent is or comprises fibronectin.
9627 . The method of claim 9612 wherein the fibrosing agent is or comprises bleomycin.
9628 . The method of claim 9612 wherein the fibrosing agent is or comprises CTGF.
9629 .- 9681 . (canceled)
9682 . The method of claim 9612 , wherein the implant is further combined with a second pharmaceutically active agent.
9683 . (canceled)
9684 . The method of claim 9612 wherein the implant is further combined with an agent that inhibits infection.
9685 - 10247 . (canceled)Join the waitlist — get patent alerts
Track US2006240063A9 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.